

# Juliane Friemel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3069540/publications.pdf>

Version: 2024-02-01

9  
papers

369  
citations

1307594

7  
h-index

1588992

8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

866  
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306.	3.1	12
2	Vertebrate lonosome kinase modulates the hepatocyte secretome to prevent perivascular liver fibrosis and inflammation. <i>Journal of Cell Science</i> , 2022, , .	2.0	2
3	Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2021, 185, 179-191.	3.7	12
4	Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. <i>Leukemia</i> , 2020, 34, 2688-2703.	7.2	52
5	Immunohistochemical biomarker expression in gastro-entero-pancreatic neuroendocrine tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15673-e15673.	1.6	0
6	Characterization of HCC Mouse Models: Towards an Etiology-Oriented Subtyping Approach. <i>Molecular Cancer Research</i> , 2019, 17, 1493-1502.	3.4	23
7	Liver cancer with concomitant TP53 and CTNNB1 mutations: a case report. <i>BMC Clinical Pathology</i> , 2016, 16, 7.	1.8	9
8	Intratumor Heterogeneity in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1951-1961.	7.0	251
9	Intratumor heterogeneity in HCC. <i>Aging</i> , 2015, 7, 350-351.	3.1	8